Sun Pharmaceutical Industries today said that it has received the US Food and Drug Administration's nod to market a generic version of alprazolam, an anti-anxiety drug, in the US market.
The company has received the USFDA's nod for marketing generic alprazolam tablets in four strengths -- 0.25 mg, 0.55 mg, 1 mg and 2 mg -- in the US market, Sun Pharma said in a statement.
Generic alprazolam tablets are equivalent to Pfizer's patented Xanax tablets. Alprazolam has annual sales of USD 145 million in the United States.
On Thursday, the company had received the US health regulator's nod for marketing a generic version of the Keppra injection, used for treating epilepsy, in the American market.
The annual sales estimation for Levetiracetam injections in the US is USD 85 million, the company said.
Shares of Sun Pharma were trading at Rs 1,695 in the late afternoon trade on BSE, down 0.37 per cent from its previous close.
